key: cord-1017245-hplev9xl
authors: Caballero Van Dyke, Marley C.; Mead, Heather L.; Bryant, Mitchell; Laux, Klaire L.; Kollath, Daniel R.; Coyne, Vanessa K.; Miller, Karis J.; Stone, Nathan E.; Jaramillo, Sierra A.; Keim, Paul; Milikowski, Clara; Gupta, Vineet K.; Vickers, Selwyn M.; Saluja, Ashok K.; Velagapudi, Mohana R.; Barker, Bridget M.
title: The Effect of Minnelide against SARS-CoV-2 in a Murine Model
date: 2021-05-06
journal: bioRxiv
DOI: 10.1101/2021.05.05.442875
sha: 39253566dc6235c82204d5fe3954f500946f05b5
doc_id: 1017245
cord_uid: hplev9xl

Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, is the causative agent of coronavirus disease 2019, COVID-19, and the current COVID-19 pandemic. Even as more vaccine candidates are released, more treatment options are critically needed. Here, we investigated the use of Minnelide, a water soluble pro-drug with anti-inflammatory properties, for the treatment of COVID-19. To do this, k18-hACE2 mice were infected with SARS-CoV-2 or given PBS control intranasally. The next day mice were either treated daily with low dose (0.0025mg/day) or high dose Minnelide (0.005mg/day), or given vehicle control intraperitoneal. Mice were weighed daily, and sacrificed at day 6 and 10 post-infection to analyze viral burden, cytokine response, and pathology. We observed a reduction in viral load in the lungs of Minnelide-treated mice infected with SARS-CoV-2 at day 10 post-infection compared to day 6 post-infection. All SARS-CoV-2 infected non-treated mice were moribund six days post-infection while treatment with Minnelide extended survival for both low (60% survival) and high (100% survival) dose treated mice ten days post-infection. Interestingly, cytokine analysis demonstrated a significant reduction in IL-6 (lung and heart) and D-dimer (serum) in high dose treated SARS-CoV-2 infected mice compared to mice infected with SARS-CoV-2 alone at day 6 post-infection. Additionally, histology analysis revealed that Minnelide treatment significantly improved lung pathology ten days post-infection with SARS-CoV-2 with all the mice exhibiting normal lung tissue with thin alveolar septa and no inflammatory cells. Overall, our study exhibits potential for the use of Minnelide to improve survival in COVID-19 patients.

Introduction 41

Coronavirus disease 2019 is an infectious respiratory disease caused by a novel 42 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] . This novel viral disease was 43 first recognized in December 2019 in Wuhan City, China and has since spread rapidly throughout the 44 world, and subsequently causing the worst global pandemic of recent times with more than 140 45 million confirmed cases and more than 3 million deaths worldwide [2] . Patients with COVID-19 46 most commonly report fever, chills, fatigue, cough, shortness of breath, and difficulty in breathing 47 which may appear 2-14 days after exposure to the virus. In some cases, patients also have increased 48 sputum production, anosmia, dyspnea, ageusia, headache, hemoptysis, diarrhea, and myalgia [3, 4] . 49

Interestingly, roughly 20% percent of patients did not show any symptoms but still have capacity to 50 transmit disease to other healthy individuals making this disease difficult to control [5] . In general, 51 adults with SARS-CoV-2 infection can be grouped into the following severity of illness categories 52 [6] . Asymptomatic or Presymptomatic Infection: Individuals who test positive for SARS-CoV-2 53 using a virologic test (i.e., a nucleic acid amplification test or an antigen test) but who have no 54 symptoms that are consistent with COVID-19. Mild Illness: Individuals who have any of the various 55 signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, 56 nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, 57 or abnormal chest imaging. Moderate Illness: Individuals who show evidence of lower respiratory 58 disease during clinical assessment or imaging and who have saturation of oxygen (SpO2) ≥94% on 59 room air at sea level. Severe Illness: Individuals who have SpO2 <94% on room air at sea level, a 60 ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, 61 respiratory frequency >30 breaths/min, or lung infiltrates >50%. Critical Illness: Individuals who 62 have respiratory failure, septic shock, and/or multiple organ dysfunction. However, the criteria for 63 each category may overlap or vary across clinical guidelines and clinical trials, and a patient's 64 clinical status may change over time. Mortality among these patients mainly occurs through the 65 development of viral pneumonia-induced acute respiratory distress syndrome (ARDS). 66

In ARDS, SARS-CoV-2 infection triggers a dysfunctional immune response causing a 67 cytokine storm which causes most of the damage to the lung. COVID-19 patients with ARDS have 68 higher level of proinflammatory cytokine like interleukin (IL)-1α, IL-1β, IL-1 receptor antagonist 69 protein (IL1RA), IL-2, IL-4, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), 70 and interferon (IFN)-gamma in blood compared to healthy controls [4, 7] . Further analysis of 71 Bronchoalveolar lavage fluid (BALF) in patients with severe COVID-19 also showed higher levels 72 of IL-6, . Single-cell RNA sequencing analysis of BALF showed enrichment of 73 proinflammatory monocyte-derived macrophages in patients with severe binding to the human angiotensin-converting enzyme 2 (ACE2) receptor [12] . ACE2 is 84 predominantly expressed in the epithelium of the human lung, small intestine, and oral mucosa [12, 85 13 ] and therefore provide route of infection. Once inside the cell, the viral genome is transcribed by 86 the viral RNA-dependent RNA polymerase and subsequently translated using host ribosomes to 87 synthesize viral proteins. Finally, mature virions are assembled and packaged in the cytoplasm of the 88 infected cell and subsequently released through exocytosis. ACE2 expression often determines the 89 susceptibility for COVID-19 infection. For example, children express very low level of ACE2 which 90 makes them less susceptible to SARS-CoV-2 infection compared to adults [14] . Notably, structural 91 differences between mouse ACE2 and the human counterpart makes it unsuitable for the spike 92 protein of SARS-CoV-2 and therefore it does not facilitate the entry of the virus into the cells. As a 93 result, wild-type laboratory mice are not suitable for SARS-CoV-2 infection studies. However, new 94 studies demonstrate the ability of variants of concern (VOCs) to infect common laboratory mice [15] . 95

To study SARS-CoV-2 pathogenesis and potential treatment options, the ideal model is the K18-96 hACE2-transgenic mice because SARS-CoV-2 infection in these mice replicates human pulmonary 97 disease similar to COVID-19. This is due to human-like ACE-2 expression driven by the epithelial 98 cell cytokeratin-18 (K18) promoter, which expresses ACE-2 in epithelial cells [16] . This mouse 99 model was initially developed by Tseng, C. et al [17] for the study of SARS-CoV pathogenesis. 100 SARS-CoV-2 also uses ACE-2 for the entry of virus into the host cell, and mimics respiratory 101 disease similar to severe COVID-19 in humans [18] . 102

Minnelide is a water soluble pro drug of an anti-inflammatory active diterpene triepoxide 103 compound triptolide which was purified from a Chines herb Tripterygium wilfordii Hook F [19] . 104

Historically, triptolide has been used for the therapy of arthritis in traditional Chinese medicine for 105 more than two thousand years. Triptolide has been documented to decrease inflammation by 106 decreasing NF-kB activity [20] [21] [22] leading to a decrease in production of inflammatory cytokines like 107 IL-6 [23] and IL-1β [24] . Triptolide, the active component of this drug is also reported to inhibit 108 acute lung injury in murine models [25] . Additionally, unpublished preclinical studies from our 109 laboratory show that in a mouse model of pulmonary fibrosis, Minnelide was highly effective in 110 decreasing fibrosis and showed improvement in various lung functions. In a mouse model of 111 pancreatic cancer, Minnelide showed a decrease in IL-1β as well as NF-kB activity [20, 26] . Anti-112 inflammatory and anti-fibrotic properties of Minnelide not only makes it an ideal candidate for early 113 therapeutic intervention against COVID-19 patients, who develop ARDS because of hyperactive 114 immune response and cytokine storm, but also makes it suitable for depleting fibrosis caused by 115 COVID-19 associated lung injury. In the current study, we show that Minnelide treatment 116 significantly improved survival of K18-hACE2 mice infected with SARS-CoV-2. Further analysis 117 showed significant reduction in SARS-CoV-2 viral burden in lungs of Minnelide treated mice. Our 118 results also show that Minnelide treatment elicited an anti-inflammatory response against SARS-119

CoV-2 resulting in improved lung histology and thereby highlighting its therapeutic potential in 120 COVID-19 patients suffering from ARDS. Table S1 and S2). In the brain, the highest levels of viral 130 burden were detected in SARS-CoV-2 non-treated mice and low dose treated mice at day 6 post-131 infection ( Figure 2 ; Table S1 ). Mice infected with SARS-CoV-2 and treated with high dose of 132

Minnelide still exhibited a high viral load at day 6 post-infection ( Figure 2 ; Table S1 ). For day 10 133 post-infection, the brain did exhibit less viral burden in both the low dose and high dose Minnelide 134 treated groups compared to day 6 post-infection, although not significant ( Figure 2 ; Table S1 ). In the 135 lung, there was high viral load detected at day 6 post-infection across all groups, SARS-CoV-2 136 infected non-treated mice, low dose, and high dose Minnelide treated mice infected with SARS-CoV-137 2 ( Figure 2 ; Table S2 ). At day 10 post-infection, there was a lower level of viral burden in both the 138 low and high dose treated mice infected with SARS-CoV-2, although not significant ( Figure 2 ; Table  139 S2). Together, these results indicate that Minnelide treatment results in a measurable, but not 140 statistically significant reduction in viral burden. 141 Additionally, weights of mice were monitored daily. All non-infected control mice remained 152 within +/-1g of their starting weight during the course of the experiment ( Figure 3B ). In contrast, all 153 mice infected with SARS-CoV-2 not treated with Minnelide experienced a significant weight loss 154 between day 4 and day 6 post-infection with no mice surviving past this time point; these mice were 155 moribund (defined as a weight drop of >20%) and euthanized on day six ( Figure 3B ). The infected 156 mice that received Minnelide therapy experienced less weight loss than infected mice without 157 therapy. The increase in drug dosage, 0.005mg/day treated mice, demonstrated less weight loss 158 compared to low dose, 0.0025mg/day treated mice, although no statistical significance was found 159 ( Figure 3B ). All mice demonstrated weight loss between days 4-6 post-infection. Interestingly, mice 160 that received treatment recovered their weight after day 6 post-infection. This is clearly demonstrated 161 by the high dose treated mice, because none succumbed to the infection in that group ( Figure 3B ). 162

All mice infected with SARS-CoV-2 and without Minnelide treatment were euthanized on day 6 163 post-infection due to extreme weight loss. 164

Next, we evaluated select cytokines (IL-6, D-dimer, and Fibrinogen) in the lung, heart, and 165 serum in mice infected with SARS-CoV-2 and treated with Minnelide on days 6 and 10 post-166 infection. For IL-6 in the lungs and heart, we observed a significant reduction in IL-6 production in 167 mice infected with SARS-CoV-2 treated with high dose Minnelide at day 6 post-infection compared 168

to SARS-CoV-2 alone ( Figure 4A ). We observed no significant differences in IL-6 in the serum 169 across all groups ( Figure 4G ). For D-dimer, there was a significant reduction in the lungs at day 10 170 post-infection in both low and high dose treated mice infected with SARS-CoV-2 compared to 171 vehicle control mice ( Figure 4B ). At day 6 post-infection, we observed a significant reduction in D-172 dimer in the serum of mice treated with low and high dose Minnelide compared to mice infected with 173 SARS-CoV-2 alone and not treated ( Figure 4H ). We observed no significant differences in D-dimer 174 production in the heart across groups ( Figure 4E ). For Fibrinogen, the data show significant reduction 175 at day 10 post-infection in mice treated with high dose Minnelide compared to low dose Minnelide 176 infected with SARS-CoV-2 ( Figure 4C ). There were no significant differences for Fibrinogen 177 production in the heart or serum across groups ( Figure 4F and 4I). 178

Lastly, we sought to determine the effect of Minnelide treatment on the pathology of mice 180 infected with SARS-CoV-2. Figure 5A is representative of the five mice treated with saline only that 181 were all sacrificed on day 10 and shows normal lung tissue with thin alveolar septa without increase 182 in inflammatory cells. Figure 5B is representative of the five mice that were treated with high dose 183

Minnelide (0.005mg) alone that were all sacrificed on day 10 with similar findings to the saline only 184 group. Figure 5C is representative of the six mice infected with virus without treatment that were 185 sacrificed on day 6. Three of the mice from the virus only group (50%) showed focal widening of 186 alveolar septa with mild increase in small mononuclear cells (lymphocytes) and increased capillaries 187 ( Figure 5C ). Figures 5D-5I are representative of the group of nine mice (eight mice lungs reviewed) 188 five of which were sacrificed on day 6 ( Figures 5D-5F ) and four of which were sacrificed on day 10 189 ( Figures 5G-5I ) all of which were infected with virus and treated with low dose Minnelide 190 (0.0025mg). On day 6, lungs showed alveolar findings that were similar to the control group with 191 normal findings with the exception of one mouse that showed platelet aggregates in blood vessels 192 ( Figures 5E and 5F ). Of the three mice that were sacrificed on day 10, all (100%) Briefly, a t175 flask that was ~50% confluent was infected with SARS-CoV-2 virus, whereby 10 mL 282 of fresh 2% FBS growth media containing 100µL of the BEI viral stock was added to VeroE6 cells 283 and gentle rocked on a rocking platform for 1 h at room temperature. 15 mL of additional 2% FBS 284 growth media was then added to the flask to bring the final volume to 25 mL. The flask was 285 incubated for 7 days at 37°C in 5% CO2 and inspected for viral replication at day 7; cell 286 death/rounding was used as a proxy for successful viral propagation and was observed by inverted 287 microscope. The cells/virus were then subjected to three freeze/thaw cycles at -80°C to maximize the 288 release of virus from cells. The contents were removed from the flask and placed in a 50mL conical 289 tube that was centrifuged at 500 × g at 4°C for 15 min to separate the cellular debris from the 290 supernatant containing the virus. 1 mL aliquots of the supernatant (viral stocks) were stored at -80°C 291 for future use. 292 293 Concentration of the viral stocks were determined by plaque assay. 6-well plates (CLS3516; 294 Millipore Sigma) were seeded with ∼3.0 × 10 5 cells/well and incubated for 48 to 72 h at 37°C in 5% 295 CO2 until 80 to 90% confluency was reached. The viral stock was serially diluted in serum free 296

Dulbecco's MEM (DMEM; Millipore Sigma, USA). Serial dilutions were prepared as follows; 30µL 297 of stock virus was added to 270µL DMEM to create a 10 -1 stock, 30µL of this stock was then added 298 to 270µL of DMEM to create a 10 -2 stock. This continued to create 10 -3 , 10 -4 , and 10 -5 viral stocks. 299

Prior to infection, the growth medium was replaced with fresh medium containing 2% FBS and 300 infected with 100µL of each SARS-CoV-2 dilution; dilutions 10 -1 through 10 -5 were tested in 301 triplicate. The 6-well plates were briefly rocked on a rocking platform and set to incubate for 1 hour 302 at 37°C in 5% CO2. Medium was then replaced with a 1× Dulbecco's MEM (DMEM, Millipore 303 at room temperature for 15 min and incubated for 120 h at 37°C in a 5% CO2 atmosphere. Then, 305 2.0 ml of 4% paraformaldehyde was added to each overlay for 30 min, followed by staining with 1% 306 crystal violet, removal of the overlay, and a triple rinse with phosphate-buffered saline (PBS). 307

Uninfected cells were included as a control for all experiments and SARS-CoV-2 manipulations were 308 conducted in a BSL-3 facility. PFUs were counted and averaged for each dilution. The concentration 309 of undiluted viral stocks used for the animal experiments described herein was determined to be 310 1x10 5 PFU/mL. Further dilution was completed in PBS to the infection concentration of 2000 PFU. 311 ketamine/xylazine (100/10 mg/kg) and cardiac puncture was performed to collect blood for cytokine 320 analysis along with brain, lung, and heart excised using aseptic technique. Partial lung and heart were 321 homogenized in 1 ml of sterile PBS for cytokine analysis. Brain, partial lung and heart were 322 processed for histology and/or measurement of viral load using RT-qPCR. For animals that reached 323 humane euthanasia endpoints at any time, or those surviving the duration of the experiments, the 324 brain, heart, lung, and serum were obtained at necropsy and processed for histology, ELISA, and 325 measurement of viral load using RT-qPCR, respectively. 326

The left lobe and partial brain from each mouse was weighed (0.05-100mg) and placed in a 328 prefilled bead tube containing 1.00mm glass beads (Beadbug, Z763756) and 600µl of lysis buffer 329 with 1% BME from the Purelink RNA mini kit (Invitrogen, USA). The tissue was homogenized for 1 330 minute disruption at 5 m/s and 1 min cooling in ice, repeated twice. Tubes were spun at 2000g for 5 331 minutes at 4°C. RNA was isolated using kit directions including incorporation of homogenizer tubes 332 (Invitrogen, 12183026) to remove remaining animal tissue. 333

One step RT-qPCR was conducted to detect the viral RNA load in each sample using Reliance System, as previously described (32). Each qPCR was prepared as a 20µL reaction containing 340 12.5μL molecular grade H2O, 5μL 4X Reliance Supermix (1x final concentration), 0.2μL forward 341 primer, 0.2μL reverse primer, and 0.1μL probe, with 2μL template RNA. During the RT-qPCR, 342 reverse transcription occurred at 50°C for 10 minutes followed by a hot start step at 95°C for 10 343 minutes. This was followed by denaturation at 95°C for 10 seconds and annealing at 60°C for 30 344 seconds which were repeated for a total of 40 cycles. Viral copy number was extrapolated using 345 synthetically generated internal qPCR standards as previously described (32). 346

Serum was collected in BD Vacutainer TM tubes (ThermoFisher, USA). Samples were processed 348 by centrifuging 3500 RPM for 5-10 minutes, supernatant collected, and protease inhibitor added 349 (Halt™ cocktail, ThermoFisher, USA). Heart and lung were excised and homogenized in 1mL of ice-350 cold sterile PBS, an antiprotease buffer solution containing PBS, protease inhibitors (inhibiting 351 cysteine, serine, and other metalloproteinases), and 0.05% Triton X-100 was added to the 352 homogenate and then clarified by centrifugation 3500 RPM for 10 minutes. Supernatants were 353 assayed for the presence of IL-6, which was quantified using an Invitrogen ELISA kit 354 (ThermoFisher, USA); and DDimer and Fibrinogen were quantified using Biomatik ELISA kits 355 (Biomatik Corporation, Ontario, Canada). 356

Tissues were fixed in histology cassettes suspended in 10% formalin (Sigma Aldrich) for 48 358 hours. Histology cassettes of fixed tissues were then fixed using the routine overnight non-fat cycle 359 on the Excelsior AS (Thermo Scientific) and embedded in paraffin wax (Histoplast LP, Fisher 360 Scientific). Tissues were sectioned in 5µm thin sections onto charged slides and heat fixed overnight 361 at 45℃. Sections were then processed for H&E staining and submitted to pathologist for analysis. 362

Differences in data were tested for significance using either GraphPad Prism for Windows 364 (GraphPad, USA). For details of the statistical test applied, refer to the figure legends. P < 0.05 were 365 considered significant. 366

Funding provided by Minneamrita Therapeutics LLC to NAU. 

The trinity of 374 COVID-19: immunity, inflammation and intervention

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, 379 China

Clinical and immunological features of severe and moderate coronavirus 382 disease 2019

Occurrence and transmission potential of asymptomatic and 385 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis

Clinical Spectrum of SARS-CoV-2 Infection

Imbalanced Host Response to SARS-CoV-391

Drives Development of COVID-19

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-394 19

Whole-Exome Sequencing Reveals Mutations 397 in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation 398 Syndrome in Fatal Cases of H1N1 Influenza

The Immunology of

The epidemiology and pathogenesis of 402 coronavirus disease (COVID-19) outbreak

Structure, Function, and Evolution of Coronavirus Spike Proteins

High 406 expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

COVID-19: Unanswered questions on 409 immune response and pathogenesis

The B1.351 and P.1 variants 412 extend SARS-CoV-2 host range to mice

SARS-CoV-2 infection in K18-ACE2 transgenic mice 414 replicates human pulmonary disease in COVID-19

Severe acute respiratory syndrome 417 coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 418 virus receptor

K18-hACE2 mice 421 develop respiratory disease resembling severe COVID-19

A preclinical evaluation of Minnelide 424 as a therapeutic agent against pancreatic cancer

Inhibition of NF-kappa B pathway leads to deregulation of epithelial-427 mesenchymal transition and neural invasion in pancreatic cancer

Triptolide 429 dysregulates glucose uptake via inhibition of IKKbeta-NF-kappaB pathway by p53 activation 430 in cardiomyocytes

Triptolide attenuates 432 lipopolysaccharide-induced inflammatory responses in human endothelial cells: involvement 433 of NF-kappaB pathway

Triptolide exerts an anti-tumor effect on nonsmall cell lung cancer cells by inhibiting 436 activation of the IL6/STAT3 axis

Anti-angiogenic effect of triptolide in rheumatoid arthritis by targeting angiogenic cascade

Anti-441 inflammatory effects of triptolide by inhibiting the NF-kappaB signalling pathway in LPS-442 induced acute lung injury in a murine model

NFkappaB-Mediated Invasiveness in CD133(+) Pancreatic TICs Is 445 Regulated by Autocrine and Paracrine Activation of IL1 Signaling

Respiratory Pathophysiology of

Mechanically Ventilated Patients with COVID-19: A Cohort Study

D-dimer in venous thromboembolism

Prevalence and Outcomes of 454 D-Dimer Elevation in Hospitalized Patients With COVID-19

Venous thromboembolism in COVID-19 patients

Understanding the COVID-19 coagulopathy spectrum

Stenoparib, an Inhibitor 463 of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and 464 HCoV-NL63 Human Coronaviruses in vitro mBio

Figure 2. Viral burden of SARS-CoV-2 Infected Mice Treated with Minnelide

PFU of SARS-CoV-2 and were treated twice daily 489 via oral gavage with either low dose (0.0025mg) or high dose (0.005mg) of Minnelide. At days 6 and 490 10 post infection, brain and lung were excised, homogenized, and RNA was extracted. RNA data is 491 cumulative of one experiment using 3-6 mice per group per experiment